Le groupe Atos reçoit une offre ferme de l’Etat français pour l’acquisition d’une partie de son ancienne activité de Calcul Avancé
Le groupe Atos reçoit une offre ferme de l'Etat français pour l'acquisition d'une partie de son ancienne activité de Calcul Avancé Les Activités de Vision AI sont exclues de la…
Une analyse « Late Breaking » démontre les caractéristiques associées à la survie globale à long terme des patients avec un adénocarcinome pancréatique métastatique traités par Onivyde®
L’essai de Phase III NAPOLI 3 est la plus grande étude interventionnelle réalisée à ce jour avec la plus longue période de suivi des patients avec un adénocarcinome pancréatique métastatique1.L’analyse…
Arvinas and Pfizer’s Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with an estrogen receptor 1…
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability and promising clinical activity with ongoing deep and durable…
Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma
Phase III NAPOLI 3 trial is the largest and has the longest follow-up for an interventional study in metastatic pancreatic adenocarcinoma1 Post-hoc analysis of NAPOLI 3 study determined characteristics associated…
Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing
Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p
New data show Roche’s Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer
The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer, compared with palbociclib and fulvestrant alone1The PIK3CA mutation…
Започнатото строителство според застроената площ е най-малкото от 2021 година насам.
Започнатото строителство според застроената площ е най-малкото от 2021 година насам. През първото тримесечие на 2025 година са започнати жилищни сгради с площ от 739 хил. кв. метра, от които…
Robex annonce la finalisation de son introduction en bourse
QUÉBEC, 31 mai 2025 (GLOBE NEWSWIRE) -- Robex Resources Inc. (« Robex » ou la « Société ») (TSX-V : RBX), producteur et développeur aurifère ouest-africain, a le plaisir d’annoncer…
Честит Гергьовден!
Честит Гергьовден!Нека Свети Георги бъде наш щит срещу злото, меч в борбата със злото и съмненията и пламък, който осветява пътя ни най-накрая към една независима държава.От нас зависи пожеланията…